Seminars in Colon & Rectal Surgery
Volume 17, Issue 2 , Pages 55-60 , June 2006

Probiotics in Inflammatory Bowel Disease

  • John Keohane, MB, MRCPI
    • ,
  • Shomik Sibartie, MB, MRCSI
    • ,
  • Fergus Shanahan, MD, FACP, FRCPI

      Affiliations

    • Corresponding Author InformationAddress reprint requests to: Prof. Fergus Shanahan, MD, Alimentary Pharmabiotic Centre, Dept. Medicine, Clinical Science Building, Cork University Hospital, Cork, Ireland.

References 

  1. Shanahan F . Immunology (Therapeutic manipulation of gut flora) . Science . 2000;289:1311–1312
  2. Askling J , Grahnquist L , Ekbom A , et al.   Incidence of paediatric Crohn’s disease in Stockholm, Sweden . Lancet . 1999;354:1179
  3. Elson CO . Commensal bacteria as targets in Crohn’s disease . Gastroenterology . 2000;119:254–257
  4. Shanahan F . Probiotics and inflammatory bowel disease: is there a scientific rationale? . Inflamm Bowel Dis . 2000;6:107–115
  5. Simon GL , Gorbach SL . Intestinal flora in health and disease . Gastroenterology . 1984;86:174–193
  6. Shanahan F . Crohn’s disease . Lancet . 2002;359:62–69
  7. Duchmann R , Kaiser I , Hermann E , et al.   Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease . Clin Exp Immunol . 1995;102:448–455
  8. Macpherson A , Khoo UY , Forgacs I , et al.   Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria . Gut . 1996;38:365–375
  9. Ursing B , Alm T , Barany F , et al.   A comparative study of metronidazole and sulfasalazine for active Crohn’s disease: the cooperative Crohn’s disease study in Sweden . Gastroenterology . 1982;83:550–562
  10. Swidsinski A , Ladhoff A , Pernthaler A , et al.   Mucosal flora in inflammatory bowel disease . Gastroenterology . 2002;122:44–54
  11. Schultsz C , Van Den Berg FM , Ten Kate FW , et al.   The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls . Gastroenterology . 1999;117:1089–1097
  12. Ogura Y , Bonen DK , Inohara N , et al.   A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease . Nature . 2001;411:603–606
  13. Sellon RK , Tonkonogy S , Schultz M , et al.   Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice . Infect Immunol . 1998;66:5224–5231
  14. Rath HC , Herfarth HH , Ikeda JS , et al.   Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats . J Clin Invest . 1996;98:945–953
  15. Guarner F , Schaafsma GJ . Probiotics . Int J Food Microbiol . 1998;39:237–238
  16. Dunne C , O’Mahony L , Murphy L , et al.   In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings . Am J Clin Nutr . 2001;73:386S–392S
  17. Rachmilewitz D , Karmeli F , Takabayashi K , et al.   Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis . Gastroenterology . 2002;122:1428–1441
  18. Vandenbroucke K , Hans W , Van HJ , et al.   Active trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice . Gastroenterology . 2004;127:502–513
  19. Steidler L , Hans W , Schotte L , et al.   Treatment of murine colitis by Lactococcus lactis secreting interleukin-10 . Science . 2000;289:1352–1355
  20. Allen SJ, Okoko B, Martinez E, et al: Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev 4:CD003048, 2003
  21. O’Mahony L , McCarthy J , Kelly P , et al.   Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationships to cytokine profiles . Gastroenterology . 2005;128:541–551
  22. McCarthy J , O’Mahony L , O’Callaghan L , et al.   Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance . Gut . 2003;52:975–980
  23. O’Mahony L , Feeney M , O’Halloran S , et al.   Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice . Aliment Pharmacol Ther . 2001;15:1219–1225
  24. Madsen KL , Doyle JS , Jewell LD , et al.   Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice . Gastroenterology . 1999;116:1107–1114
  25. Coeuret V , Gueguen M , Vernoux JP . Numbers and strains of lactobacilli in some probiotic products . Int J Food Microbiol . 2004;97:147–156
  26. Plein K , Hotz J . Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn’s disease with special respect to chronic diarrhoea—a pilot study . Z Gastroenterol . 1993;31:129–134
  27. Guslandi M , Mezzi G , Sorghi M , et al.   Saccharomyces boulardii in maintenance treatment of Crohn’s disease . Dig Dis Sci . 2000;45:1462–1464
  28. Malin M , Suomalainen H , Saxelin M , et al.   Promotion of IgA immune response in patients with Crohn’s disease by oral bacteriotherapy with Lactobacillus GG . Ann Nutr Metab . 1996;40:137–145
  29. Gupta P , Andrew H , Kirschner BS , et al.   Is lactobacillus GG helpful in children with Crohn’s disease? (Results of a preliminary, open-label study) . J Pediatr Gastroenterol Nutr . 2000;31:453–457
  30. Prantera C , Scribano ML , Falasco G , et al.   Ineffectiveness of probotics in preventing recurrence after curative resection for Crohn’s disease: a randomised control trial with Lactobacillus GG . Gut . 2002;51:405–409
  31. Campieri M , Rizzello F , Venturi A , et al.   Combination of antibiotic and probiotic is efficacious in prophylaxis of post operative recurrence of Crohn’s disease: a randomised control study vs mesalazine . Gastroterology . 2000;118:A781; (abstr)
  32. Kruis W , Schutz E , Fric P , et al.   Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis . Aliment Pharmacol Ther . 1997;11:853–858
  33. Kruis W , Fric P , Pokrotnieks J , et al.   Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine . Gut . 2004;53:1617–1623
  34. Biblioni R , Fedorak RN , Tannock GW , et al.   VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis . Am J Gastroenterol . 2005;100:1539–1546
  35. Ishikawa H , Akedo I , Umesaki Y , et al.   Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis . J Am Coll Nutr . 2003;22:56–63
  36. Cui HH , Chen CL , Wang JD , et al.   Effects of probiotic on intestinal mucosa of patients with ulcerative colitis . World J Gastroenterol . 2004;10:1521–1525
  37. Furrie E , Macfarlane S , Kennedy A , et al.   Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial . Gut . 2005;54:242–249
  38. Guslandi M , Giollo P , Testoni PA . A pilot trial of Saccharomyces boulardii in ulcerative colitis . Eur J Gastroenterol Hepatol . 2003;15:697–698
  39. Fazio VW , Ziv Y , Church JM , et al.   Ileal pouch-anal anastomoses complications and function in 1005 patients . Ann Surg . 1995;222:120–127
  40. Meagher AP , Farouk R , Dozois RR , et al.   J ileal pouch-anal anastomosis for chronic ulcerative colitis complications and long-term outcomes in 1310 patient . Br J Surg . 1998;85:800–803
  41. Sandborn WJ , Tremaine WJ , Batts KP , et al.   Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index . Mayo Clin Proc . 1994;69:409–415
  42. Sandborn WJ . Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment . Gastroenterology . 1994;107:1856–1860
  43. Ruseler-van Embden JG , Schouten WR , van Lieshout LM . Pouchitis: result of microbial imbalance? . Gut . 1994;35:658–664
  44. Gionchetti P , Rizzello F , Venturi A , et al.   Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial . Gastroenterology . 2000;119:305–309
  45. Mimura T , Rizzello F , Helwig U , et al.   Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis . Gut . 2004;53:108–114
  46. Gionchetti P , Rizzello F , Hellwig U , et al.   Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial . Gastroenterology . 2003;124:1202–1209
  47. Shen B , Brzezinski A , Fazio VW , et al.   Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice . Aliment Pharmacol Ther . 2005;22:71–78
  48. Kuisma J , Mentula S , Jarvinen H , et al.   Effects of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora . Aliment Pharmacol Ther . 2003;17:509–515
  49. Laake KO , Line PD , Grzyb K , et al.   Assessment of mucosal inflammation and blood flow in response to four weeks’ intervention with probiotics in patients operated with a J-configurated ileal-pouch-analanastomosis (IPAA) . Scand J Gastroenterol . 2004;39:1228–1235
  50. Gooselink MP , Schouten WR , van Lieshout LM , et al.   Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG . Dis Colon Rectum . 2004;47:876–884
  51. Malchow HA . Crohn’s disease and Escherichia coli (A new approach in therapy to maintain remission of colonic Crohn’s disease?) . J Clin Gastroenterol . 1997;25:653–658
  52. McCarthy J , O’Mahony L , Dunne C , et al.   An open trial of a novel probiotic as an alternative to steroids in mild/moderately active Crohn’s disease . Gut . 2001;49(suppl III):2447; (abstr)
  53. Schultz M , Timmer A , Herfarth HH , et al.   Lactobacillus GG in inducing and maintaining remission if Crohn’s disease . BMC Gastroenterol . 2004;15:4–5
  54. Rembacken BJ , Snelling AM , Hawkey PM , et al.   Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial . Lancet . 1999;354:635–639
  55. Venturi A , Gionchetti P , Rizzello F , et al.   Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis . Aliment Pharmacol Ther . 1999;13:1103–1108
  56. Friedman G , George J . Treatment of refractory “pouchitis” with prebiotic and probiotic therapy . Gastroenterology . 2000;118:A4167; (abstr)

PII: S1043-1489(06)00055-8

doi: 10.1053/j.scrs.2006.06.001

Seminars in Colon & Rectal Surgery
Volume 17, Issue 2 , Pages 55-60 , June 2006

Article Tools